Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study

被引：0
|
作者：
Mao, R. [1 ]
He, Y. [1 ]
Ben-Horin, S. [2 ]
Chen, M. -H. [1 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China
[2] Sheba Med Ctr, Tel Aviv, Israel
来源：
JOURNAL OF CROHNS & COLITIS | 2017年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P441
引用
收藏
页码：S300 / S301
页数：2
相关论文
共 50 条
  • [31] An open-label safety, tolerability, and efficacy study of natalizumab in adolescents with moderately to severely active Crohn's disease
    Hyams, J
    Wilson, D
    Thomas, A
    Mitchell, B
    Daniels, G
    Zanker, S
    Kugathasan, S
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10) : S256 - S256
  • [32] Clinical efficacy of treatment with Infliximab in a German multicenter, prospective, open-label trial in refractory Crohn's disease.
    Schreiber, S
    Kuehbacher, T
    Mascheretti, S
    Hommel, E
    Pohl, C
    Kruis, W
    Andus, T
    Lochs, H
    Fleig, W
    Thriene, W
    GASTROENTEROLOGY, 2000, 118 (04) : A568 - A568
  • [33] Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease
    Baert, Filip
    Moortgat, Liesbeth
    Van Assche, Gert
    Caenepeel, Philip
    Vergauwe, Philippe
    De Vos, Martine
    Stokkers, Pieter
    Hommes, Daniel
    Rutgeerts, Paul
    Vermeire, Severine
    D'Haens, Geert
    GASTROENTEROLOGY, 2010, 138 (02) : 463 - 468
  • [34] The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial
    Yanai, Henit
    Levine, Arie
    Hirsch, Ayal
    Boneh, Rotem Sigall
    Kopylov, Uri
    Eran, Hagar Banai
    Cohen, Nathaniel A.
    Ron, Yulia
    Goren, Idan
    Leibovitzh, Haim
    Wardi, Joram
    Zittan, Eran
    Ziv-Baran, Tomer
    Abramas, Lee
    Fliss-Isakov, Naomi
    Raykhel, Barbara
    Gik, Tamar Pfeffer
    Dotan, Iris
    Maharshak, Nitsan
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (01): : 49 - 59
  • [35] Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab
    Laharie, D.
    Reffet, A.
    Belleannee, G.
    Chabrun, E.
    Subtil, C.
    Razaire, S.
    Capdepont, M.
    de Ledinghen, V.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (06) : 714 - 721
  • [36] Mucosal Healing With Methotrexate in Crohn's Disease: A Prospective Comparative Study With Azathioprine and Infliximab
    Laharie, David
    Reffet, Armel
    Chabrun, Edouard
    Subtil, Clement
    Razaire, Sylvie
    de Ledinghen, Victor
    GASTROENTEROLOGY, 2010, 138 (05) : S689 - S690
  • [37] Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn's disease
    Grover, Zubin
    Muir, Richard
    Lewindon, Peter
    JOURNAL OF GASTROENTEROLOGY, 2014, 49 (04) : 638 - 645
  • [38] Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn’s disease
    Zubin Grover
    Richard Muir
    Peter Lewindon
    Journal of Gastroenterology, 2014, 49 : 638 - 645
  • [39] Thalidomide induces mucosal healing in postoperative Crohn disease endoscopic recurrence: Case report and literature review
    Hu, Huiqin
    Wang, Xinying
    Liu, Side
    MEDICINE, 2016, 95 (36)
  • [40] Natalizumab maintains remission in patients with moderately to severely active Crohn's disease for up to 2-years: Results from an open-label extension study
    Parraccione, Remo
    Colombel, Jean-Frederic
    Enns, Robert
    Feagan, Brian
    Hanauer, Stephen
    Lawrance, Ian
    Rutgeerts, Paul
    Sandbom, William
    Schreiber, Stefan
    Targan, Stephan
    van Deventer, Sander
    GASTROENTEROLOGY, 2006, 130 (04) : A111 - A111
12345